Article info

Download PDFPDF
Extended report
Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial

Authors

  1. Correspondence to Dr Wolfgang Hueber, Translational Medicine—Autoimmunity, Novartis Institutes for BioMedical Research, WSJ 386.10.48, Basel CH-4002, Switzerland; wolfgang.hueber{at}novartis.com
View Full Text

Citation

McInnes IB, Sieper J, Braun J, et al
Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial

Publication history

  • Received September 10, 2012
  • Revised December 17, 2012
  • Accepted December 29, 2012
  • First published January 29, 2013.
Online issue publication 
December 30, 2013

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.